Tetramer-based quantification of cytomegalovirus (CMV)–specific CD8+ T lymphocytes in T-cell–depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection

Jan W. Gratama, Joost W. J. van Esser, Cor H. J. Lamers, Claire Tournaly, Bob Löwenberg, Reinder L. H. Bolhuis, and Jan J. Cornelissen

Recovery of cytomegalovirus (CMV)–specific T-cell–mediated immunity after allogeneic hematopoietic stem cell transplantation (SCT) is critical for protection against CMV disease. The study used fluorochrome-conjugated tetrameric complexes of HLA-A2 molecules loaded with the immunodominant NLVPMVATV (NLV) peptide derived from the CMV protein pp65 to quantify A2-NLV–specific CD8+ T cells in partially T-cell–depleted grafts administered to 27 HLA-A*0201+ patients and to monitor recovery of these T cells during the first 12 months after SCT. None of the 9 CMV-seronegative patients became infected with CMV, whereas 14 of 18 CMV-seropositive patients developed CMV antigenemia after SCT. CMV-seropositive recipients of grafts from CMV-seronegative donors required more preemptive treatment with ganciclovir (GCV) than those of grafts from CMV-seropositive donors (3 [1–6] versus 1 [0–3] courses, respectively; P = .009). The number of A2-NLV–specific CD8+ T cells in the grafts correlated inversely with the number of preemptive GCV courses administered (r = −.61; P = .01). None of the 9 CMV-seronegative patients mounted a CMV-specific immune response as measured by monitoring A2-NLV–specific CD8+ T cells after SCT. Thirteen of 14 CMV-seropositive patients without CMV disease recovered these T cells. In spite of preemptive GCV treatment, CMV disease developed in 4 patients, who all failed to recover A2-NLV–specific CD8+ T cells after SCT (P = .002). Thus, enumeration of HLA-restricted, CMV-specific CD8+ T cells in the grafts and monitoring of these T cells after SCT may constitute a rapid and sensitive tool to identify SCT recipients at risk for developing CMV disease. (Blood. 2001;98:1358-1364)

© 2001 by The American Society of Hematology
Table 1. Patient characteristics

<table>
<thead>
<tr>
<th>Patient characteristics</th>
<th>No. of patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (male/female)</td>
<td>17/10</td>
</tr>
<tr>
<td>Median age, y (range)</td>
<td>39 (16-53)</td>
</tr>
<tr>
<td>Diagnostic indication for SCT</td>
<td></td>
</tr>
<tr>
<td>Acute myelogenous leukemia</td>
<td>9</td>
</tr>
<tr>
<td>Acute lymphoblastic leukemia</td>
<td>3</td>
</tr>
<tr>
<td>Chronic myeloid leukemia</td>
<td>5</td>
</tr>
<tr>
<td>Chronic lymphocytic leukemia</td>
<td>1</td>
</tr>
<tr>
<td>Non-Hodgkin lymphoma</td>
<td>2</td>
</tr>
<tr>
<td>Multiple myeloma</td>
<td>5</td>
</tr>
<tr>
<td>Hodgkin disease</td>
<td>1</td>
</tr>
<tr>
<td>Severe aplastic anemia</td>
<td>1</td>
</tr>
<tr>
<td>Risk status (standard/high)</td>
<td>11/16</td>
</tr>
<tr>
<td>Stem cell donor type (sibling/unrelated)</td>
<td>20/7</td>
</tr>
<tr>
<td>Stem cell source (bone marrow/peripheral blood)</td>
<td>18/9</td>
</tr>
<tr>
<td>Median no. of cells grafted (range)</td>
<td></td>
</tr>
<tr>
<td>Mononuclear cells × 10^9/kg</td>
<td>1.0 (0.2-0.0)</td>
</tr>
<tr>
<td>CFU-GM × 10^9/kg</td>
<td>20.0 (4.3-128.4)</td>
</tr>
<tr>
<td>CD3+ T lymphocytes × 10^9/kg</td>
<td>0.2 (0.2-6.4)*</td>
</tr>
<tr>
<td>CMV serology before SCT</td>
<td></td>
</tr>
<tr>
<td>Recipient negative, SCT donor negative</td>
<td>6</td>
</tr>
<tr>
<td>Recipient negative, SCT donor positive</td>
<td>5</td>
</tr>
<tr>
<td>Recipient positive, SCT donor positive</td>
<td>5</td>
</tr>
<tr>
<td>Recipient positive, SCT donor positive</td>
<td>13</td>
</tr>
</tbody>
</table>

venous blood samples collected in sodium heparin were collected at 2, 3, 6, 9, and 12 months after SCT. As reference, venous blood samples were obtained from 29 controls (ie, 20 apparently healthy laboratory workers and 9 SCT donors). From the latter, the blood samples were obtained before mobilization or bone marrow donation. Absolute CD8+ T-cell counts were assessed within 6 hours after venipuncture; mononuclear cells were isolated from the remainder of the sample, cryopreserved in medium containing 10% dimethyl sulfoxide, and stored in liquid N2. CD8+ T lymphocytes were enumerated by using a 3-color, single-platform, whole-blood immunomassay technique.14 The following monoclonal antibodies were used: CD45 (clone 2D1 conjugated with fluorescein isothiocyanate [FITC]); BD Biosciences [BD], San Jose, CA), CD8 (clone SK1 conjugated with phycoerythrin [PE]; BD) and TCR PANC1 conjugated with PE-Cy5; Immunotech, Marseille, France). Of each sample, 50 000 leukocytes were acquired using a FACSCalibur flow cytometer (BD). During data analysis, CD8+ T lymphocytes were defined as events with low to medium forward light scatter (FSC), low side secondary light scatter (SSC), CD45+, TCRαβ+, and CD8+.

The proportion of CD8+ T cells binding HLA-A2-LV (A2-LV) tetramers was assessed on cryopreserved and thawed mononuclear cell suspensions and reference SCT samples. The A2-LV tetramer, conjugated with PE, was produced by Beckman-Coulter, Immunomassays Division (Marseille, France), and validated as described elsewhere.9 After thawing, cells were incubated with A2-LV tetramer and CD8 (clone SK1 conjugated with allophycocyanin). After 1 wash, cells were resuspended in phosphate-buffered saline (PBS) containing 1 μg/mL 7-aminoactinomycin D (Sigma, St Louis, MO). Following acquisition of 20 000 living CD8+ lymphocytes (defined as having low to intermediate FSC, low SSC, as well as being 7-AAD+ and CD8+), the proportion of living CD8+ T cells binding the A2-LV tetramer was assessed, and the absolute number of circulating A2-LV–specific CD8+ T cells was calculated from the proportion of CD8+ T cells binding A2-LV tetramers and the simultaneously obtained absolute CD8+ T-cell count. Of note, the A2-LV tetramer-binding T cells were CD8+ and not CD8+.9 The lower limit of detection was 0.1% A2-LV–specific CD8+ T cell (fraction of viable CD8+ T cells) and, in absolute counts, 1 A2-LV–specific CD8+ T cell/μL blood. In the stem cell grafts, the number of transplanted A2-LV–specific CD8+ T cells/kg body weight of the recipient was calculated from the proportion of CD3+ T cells coexpressing CD8 and binding A2-LV tetramers plus the simultaneously established number of CD3+ T cells/kg transplanted.

**Diagnostic tests for CMV infection and CMV disease**

CMV seropositivity was assessed by detection of immunoglobulin (Ig)M and IgG antibodies to CMV late antigen.10 The presence of CMV-specific IgG antibodies in healthy blood donors, in SCT donors, or in patients before SCT was taken as a marker for CMV carrier status. CMV antigenemia was assessed within 6 hours after venipuncture; mononuclear cells were isolated from the remainder of the sample, cryopreserved in medium containing 10% dimethyl sulfoxide, and stored in liquid N2. CD8+ T lymphocytes were enumerated by using a 3-color, single-platform, whole-blood immunomassay technique.14 The following monoclonal antibodies were used: CD45 (clone 2D1 conjugated with fluorescein isothiocyanate [FITC]); BD Biosciences [BD], San Jose, CA), CD8 (clone SK1 conjugated with phycoerythrin [PE]; BD) and TCR PANC1 conjugated with PE-Cy5; Immunotech, Marseille, France). Of each sample, 50 000 leukocytes were acquired using a FACSCalibur flow cytometer (BD). During data analysis, CD8+ T lymphocytes were defined as events with low to medium forward light scatter (FSC), low side secondary light scatter (SSC), CD45+, TCRαβ+, and CD8+.

The proportion of CD8+ T cells binding HLA-A2-LV (A2-LV) tetramers was assessed on cryopreserved and thawed mononuclear cell suspensions and reference SCT samples. The A2-LV tetramer, conjugated with PE, was produced by Beckman-Coulter, Immunomassays Division (Marseille, France), and validated as described elsewhere.9 After thawing, cells were incubated with A2-LV tetramer and CD8 (clone SK1 conjugated with allophycocyanin). After 1 wash, cells were resuspended in phosphate-buffered saline (PBS) containing 1 μg/mL 7-aminoactinomycin D (Sigma, St Louis, MO). Following acquisition of 20 000 living CD8+ lymphocytes (defined as having low to intermediate FSC, low SSC, as well as being 7-AAD+ and CD8+), the proportion of living CD8+ T cells binding the A2-LV tetramer was assessed, and the absolute number of circulating A2-LV–specific CD8+ T cells was calculated from the proportion of CD8+ T cells binding A2-LV tetramers and the simultaneously obtained absolute CD8+ T-cell count. Of note, the A2-LV tetramer-binding T cells were CD8+ and not CD8+.9 The lower limit of detection was 0.1% A2-LV–specific CD8+ T cell (fraction of viable CD8+ T cells) and, in absolute counts, 1 A2-LV–specific CD8+ T cell/μL blood. In the stem cell grafts, the number of transplanted A2-LV–specific CD8+ T cells/kg body weight of the recipient was calculated from the proportion of CD3+ T cells coexpressing CD8 and binding A2-LV tetramers plus the simultaneously established number of CD3+ T cells/kg transplanted.

**Ganciclovir therapy**

Preemptive ganciclovir (GCV) therapy (5 mg/kg intravenously twice daily) was started if CMV antigenemia tests had revealed 4 or more pp65+ leukocytes per test and was discontinued after 2 successive negative test results.10 CMV disease was treated with a combination of GCV and CMV-specific immunoglobulins.11

**Figure 1. T lymphocytes binding the HLA-A2-LV/PVR/AVTV (A2-LV) tetramer are CD8+ and not CD8+.** Following acquisition of a list mode data file containing 20 000 viable CD8+ lymphocytes, viable cells were selected on the basis of 7-AAD negativity (Gate 1). Among the viable mononuclear cells, CD8+ lymphocytes were selected on the basis of CD8 expression and a low side scatter signal (Gate 2). Lymphocytes fulfilling the criteria of Gates 1 and 2 are displayed in the figure. The percentage of A2-LV–specific CD8+ T lymphocytes was assessed and expressed as a fraction of viable CD8+ lymphocytes by using quadrant statistics. PE, phycoerythrin; APC, allophycocyanin.
Statistical methods
For nonparametric statistical analyses, Wilcoxon test and Spearman rank correlation test were used. Fisher exact test (2-sided) was used to analyze the 2-by-2 tables. P values < .05 were considered significant.

Results
CMV serology before SCT and CMV infection
Nine patients were CMV seronegative before SCT and 3 of them received grafts from a CMV-seropositive donor. None of these 9 patients became infected with CMV after SCT (Table 2).

Eighteen patients were CMV seropositive (Table 2): 5 of them received SCT from a CMV-seronegative donor and all of these 5 patients reactivated their CMV as evidenced by the appearance of pp65+ leukocytes in the blood at a median of 25 days (range: 22-47) after SCT (Table 3). These 5 patients received preemptive GCV therapy, and recurrence of CMV antigenemia required multiple courses of GCV treatment in 4 of them. Three patients developed CMV disease at 106, 236, and 253 days after SCT. CMV disease was fatal in 2 of these 3 patients, who died of CMV encephalitis (patient 4) and CMV pneumonitis (patient 5). CMV infection involved the bone marrow in patient 3 with early-onset disease (ie, day 106), but this syndrome resolved on treatment with GCV and CMV-specific immunoglobulins.

Nine of 13 CMV-seropositive recipients of SCT from a CMV-seropositive donor developed CMV antigenemia after SCT; pp65+ leukocytes became detectable at a median of 49 days (range: 17-355) after SCT (Table 3). Seven of these 9 patients received preemptive GCV therapy, and recurrence of CMV antigenemia required multiple courses of GCV treatment in 3 of these 7 patients. One patient (6) developed CMV disease of the bone marrow at 38 days after SCT, which was followed by secondary graft failure; ultimately, this patient died of CMV encephalitis despite prolonged GCV therapy.

More preemptive treatment with GCV had to be administered to CMV-seropositive recipients of grafts from CMV-seronegative donors than to those of grafts from CMV-seropositive donors (3 [1-6] versus 1 [0-3] courses, respectively; \( P = .009 \)). CMV disease occurred more frequently after SCT from a CMV-seropositive than from a CMV-seronegative donor (3 of 5 versus 1 of 13 patients, respectively; \( P = .04 \)). The higher incidence of CMV antigenemia and disease after SCT from CMV-seronegative versus CMV-seropositive donors indicates that CMV-specific \( \text{T} \) lymphocytes in the graft may protect against progressive CMV infection (see below).

| Table 2. Clinical outcome of SCT stratified by recipient CMV serology |
|-----------------|-----------------|-----------------|
|                  | CMV seronegative (n = 9) | CMV seropositive (n = 18) |
| CMV antigenemia  | 0                | 14               |
| Recurrent antigenemia* | 0            | 7                |
| CMV disease      | 0                | 4                |
| Survival status (alive/dead) | 7/2 | 13/5             |
| Cause of death   |                  |                  |
| Relapse of original disease | 0      | 0                |
| CMV disease (main cause) | 0      | 2†              |
| CMV disease (contributing) | 0      | 1‡              |
| Chronic GVHD     | 1                | 2                |

SCT, stem cell transplant; CMV, cytomegalovirus; GVHD, graft-versus-host disease.
*Requiring therapy with ganciclovir.
†Death from CMV encephalitis (n = 1) or CMV pneumonitis (n = 1).
‡Organ affected: bone marrow.

Enumeration of A2-NLV–specific CD8+ T lymphocytes
No A2-NLV–specific CD8+ T cells were detectable in the peripheral blood of 8 CMV-seronegative SCT donors tested. When expressed in absolute counts, A2-NLV–specific CD8+ T cells were above the detection limit (ie, \( \geq 1/\mu L \)) in 21 of 29 CMV-seropositive SCT donors or healthy laboratory workers. The median value was 3/\( \mu L \) (range: < 1-46). When expressed as a fraction of CD8+ T cells, A2-NLV–specific CD8+ T cells were above the detection limit (ie, \( \geq 0.1\% \) of CD8+ T cells) in 23 of the 29 CMV-seropositive individuals. The median value was 0.7% (range: < 0.1%-11.3%) of CD8+ T cells. The enumeration results expressed in relative and absolute numbers were strongly and positively correlated, both in healthy CMV-seropositive individuals and in SCT recipients (overall, Spearman rank correlation coefficient \( r = 0.94 \); Figure 2). Therefore, results are only presented in absolute numbers in the following sections.

Repopulation kinetics of A2-NLV–specific CD8+ T lymphocytes after SCT
The repopulation kinetics of total CD8+ T cells is shown in Figure 3 and that of the subset of A2-NLV–specific CD8+ T cells in Figure 4. These data are separately shown for 9 CMV-seronegative patients (Figure 3A, Figure 4A), in 4 CMV-seropositive patients without antigenemia (Figure 3B, Figure 4B), in 10 CMV-seropositive patients developing CMV antigenemia but no CMV disease (Figure 3C, Figure 4C), and in 4 patients with CMV disease after SCT (Figure 3D, Figure 4D). The rates of repopulation of total CD8+ T cells (Figure 3) in these 4 groups was not significantly different, although, among patients with active CMV infection, CD8+ T-cell repopulation in the group with CMV disease (Figure 3D) lagged behind that of the group with CMV antigenemia but without CMV disease (Figure 3C). However, differences between these latter 2 groups became significant when A2-NLV–specific CD8+ T cells were studied (Figure 4).

A2-NLV–specific CD8+ T cells remained undetectable in 8 of the 9 CMV-seronegative patients, irrespective of whether the donor was CMV seropositive or not. In 1 patient, A2-NLV–specific CD8+ T cells just reached the detection limit (ie, 1 cell/\( \mu L \)) at 3 and 6 months, to become undetectable again at 9 and 12 months after SCT (Figure 4A).

All but 1 of 14 CMV-seropositive patients without CMV disease recovered their A2-NLV–specific CD8+ T cells (ie, these cells became detectable at 2 or more occasions). The group of 10 patients developing CMV antigenemia after SCT showed a reconstitution of A2-NLV–specific CD8+ T cells to higher (ie, supranormal) levels (Figure 4C) than the group of 4 patients without CMV antigenemia in which A2-NLV–specific CD8+ T cells stayed within the normal range and even remained undetectable in 1 of them (patient 16; Figure 4B).

Most strikingly, A2-NLV–specific CD8+ T cells remained undetectable throughout the entire follow-up of 3 of the 4 patients developing CMV disease, whereas A2-NLV–specific CD8+ T cells were detected only once in the fourth patient (5) (ie, 2 cells/\( \mu L \) on day 82) but were undetectable again when CMV disease developed at day 236 (Figure 4D). Thus, CMV-seropositive SCT recipients who developed CMV viremia but reconstituted their A2-NLV–specific CD8+ T cells had a significantly lower frequency of CMV
disease than those who did not recover such T cells (1 of 11 versus 0 of 3 patients, respectively; \( P = .01 \)).

The following parameters did not significantly influence the repopulation kinetics of total CD8\(^+\) T cells (all 27 patients) or A2-NLV–specific CD8\(^+\) T cells (18 CMV-seropositive patients) at the time points studied: SCT donor type (ie, sibling versus unrelated), stem cell source (ie, bone marrow versus peripheral blood), technique of T-cell depletion (ie, sheep erythrocyte rosetting versus CD34\(^+\) cell selection), and donor CMV serology (ie, positive versus negative) (data not shown).

Transfer of A2-NLV–specific CD8\(^+\) T lymphocytes with the grafts

No A2-NLV–specific CD8\(^+\) T cells were detectable in the grafts of 5 CMV-seronegative donors tested (Table 3). The partially T-cell–depleted grafts from 10 of the 13 CMV-seropositive donors tested contained a median of 1.6 \( \times \) 10\(^3\) A2-NLV–specific CD8\(^+\) T cells/kg body weight of the recipient (range: 0.2-11.3), whereas...

Table 3. CMV antigenemia, CMV disease, and regeneration of A2-NLV–specific CD8\(^+\) T lymphocytes in CMV-seropositive SCT recipients

<table>
<thead>
<tr>
<th>Patient</th>
<th>Donor (type of SCT)</th>
<th>Donor CMV serology</th>
<th>Onset of CMV antigenemia*</th>
<th>No. of GCV treatment courses</th>
<th>CMV disease (day of onset)</th>
<th>No. in SCT†</th>
<th>Peak % in blood‡</th>
<th>Peak no. in blood§</th>
<th>Follow-up*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 (S)</td>
<td>Neg</td>
<td>47</td>
<td>1</td>
<td>—</td>
<td>&lt; 0.1</td>
<td>14.2 (59)*</td>
<td>155 (90)*</td>
<td>365</td>
<td>365</td>
</tr>
<tr>
<td>2 (U)</td>
<td>Neg</td>
<td>25</td>
<td>3</td>
<td>—</td>
<td>&lt; 0.1</td>
<td>2.1 (293)</td>
<td>14 (293)</td>
<td>365</td>
<td>365</td>
</tr>
<tr>
<td>3 (U)</td>
<td>Neg</td>
<td>55</td>
<td>3</td>
<td>106</td>
<td>&lt; 0.1</td>
<td>&lt; 1</td>
<td>&lt; 1</td>
<td>270</td>
<td>270</td>
</tr>
<tr>
<td>4 (U)</td>
<td>Neg</td>
<td>22</td>
<td>6</td>
<td>253</td>
<td>&lt; 0.1</td>
<td>0.2 (92)</td>
<td>&lt; 1</td>
<td>270</td>
<td>270</td>
</tr>
<tr>
<td>5 (S)</td>
<td>Neg</td>
<td>25</td>
<td>4</td>
<td>236</td>
<td>&lt; 0.1</td>
<td>0.2 (82)</td>
<td>2 (82)</td>
<td>238</td>
<td>238</td>
</tr>
<tr>
<td>6 (S)</td>
<td>Pos</td>
<td>38</td>
<td>3</td>
<td>38</td>
<td>&lt; 0.1</td>
<td>&lt; 0.1</td>
<td>&lt; 1</td>
<td>367</td>
<td>367</td>
</tr>
<tr>
<td>7 (S)</td>
<td>Pos</td>
<td>49</td>
<td>2</td>
<td>—</td>
<td>3.5</td>
<td>0.7 (54)</td>
<td>2 (54)</td>
<td>181</td>
<td>181</td>
</tr>
<tr>
<td>8 (S)</td>
<td>Pos</td>
<td>—</td>
<td>0</td>
<td>—</td>
<td>11.3</td>
<td>3.4 (89)</td>
<td>17 (89)</td>
<td>355</td>
<td>355</td>
</tr>
<tr>
<td>9 (S)</td>
<td>Pos</td>
<td>18</td>
<td>1</td>
<td>—</td>
<td>0.8</td>
<td>2.9 (346)</td>
<td>113 (346)</td>
<td>346</td>
<td>346</td>
</tr>
<tr>
<td>10 (U)</td>
<td>Pos</td>
<td>17</td>
<td>0</td>
<td>—</td>
<td>2.2</td>
<td>3.3 (61)</td>
<td>40 (61)</td>
<td>181</td>
<td>181</td>
</tr>
<tr>
<td>11 (U)</td>
<td>Pos</td>
<td>74</td>
<td>3</td>
<td>—</td>
<td>1.0</td>
<td>5.3 (84)</td>
<td>124 (358)</td>
<td>358</td>
<td>358</td>
</tr>
<tr>
<td>12 (S)</td>
<td>Pos</td>
<td>24</td>
<td>1</td>
<td>—</td>
<td>&lt; 0.1</td>
<td>5.4 (180)</td>
<td>36 (180)</td>
<td>180</td>
<td>180</td>
</tr>
<tr>
<td>13 (S)</td>
<td>Pos</td>
<td>—</td>
<td>0</td>
<td>—</td>
<td>3.6</td>
<td>0.5 (59)</td>
<td>2 (94)</td>
<td>365</td>
<td>365</td>
</tr>
<tr>
<td>14 (U)</td>
<td>Pos</td>
<td>143</td>
<td>0</td>
<td>—</td>
<td>0.8</td>
<td>3.8 (178)</td>
<td>19 (178)</td>
<td>339</td>
<td>339</td>
</tr>
<tr>
<td>15 (S)</td>
<td>Pos</td>
<td>357</td>
<td>1</td>
<td>—</td>
<td>&lt; 0.1</td>
<td>0.2 (180)</td>
<td>1 (94)</td>
<td>370</td>
<td>370</td>
</tr>
<tr>
<td>16 (S)</td>
<td>Pos</td>
<td>—</td>
<td>0</td>
<td>—</td>
<td>0.2</td>
<td>0.2 (123)</td>
<td>&lt; 1</td>
<td>181</td>
<td>181</td>
</tr>
<tr>
<td>17 (S)</td>
<td>Pos</td>
<td>130</td>
<td>1</td>
<td>—</td>
<td>NT</td>
<td>1.3 (60)</td>
<td>2 (180)</td>
<td>180</td>
<td>180</td>
</tr>
<tr>
<td>18 (S)</td>
<td>Pos</td>
<td>—</td>
<td>0</td>
<td>—</td>
<td>NT</td>
<td>4.3 (59)</td>
<td>5 (97)</td>
<td>270</td>
<td>270</td>
</tr>
</tbody>
</table>

CMV, cytomegalovirus; A2-NLV, NLVPMVATV peptide presented by HLA-A2; SCT, stem cell transplant; GCV, ganciclovir; S, HLA-matched sibling donor; U, HLA-matched unrelated donor; NT, not tested.

*Day after SCT.
†Number of A2-NLV-specific CD8\(^+\) T cells \( \times 10^3 \) kg body weight of the recipient.
‡Peak percentage of A2-NLV-specific CD8\(^+\) T cells (expressed as fraction of total CD8\(^+\) T cell); day on which peak percentage was observed (in parentheses).
§Peak absolute number of A2-NLV-specific CD8\(^+\) T cells \( \times 10^3 \) /mL; day on which peak absolute number was observed (in parentheses).

Figure 2. The percentages and absolute numbers of A2-NLV–specific CD8\(^+\) T cells in peripheral blood are strongly and positively correlated. On the x axis, the percentage of A2-NLV–specific CD8\(^+\) T cells (expressed as a fraction of total CD8\(^+\) cells) is shown; on the y axis, the absolute number of A2-NLV–specific CD8\(^+\) T cells (expressed in counts per microliter). Data are from 29 blood samples of 29 healthy HLA-A*0201\(^+\) CMV-seropositive SCT donors or laboratory workers (○) and from 71 blood samples obtained from 18 HLA-A*0201\(^+\), CMV-seropositive SCT recipients (●). Overall, Spearman rank correlation test is \( r = 0.94 (P < .0001) \). Logarithmic scales were used for the x and y axes to compress the figure.

Figure 3. Repopulation of total CD8\(^+\) T cells after allogeneic, T-cell-depleted SCT. (A) CMV-seronegative patients (n = 9); (B) CMV-seropositive patients without CMV antigenemia after SCT (n = 4); (C) CMV-seropositive patients developing CMV antigenemia but no CMV disease (n = 10); (D) CMV-seropositive patients developing CMV antigenemia and CMV disease (n = 4). Logarithmic scales were used for the y axes to compress the figure. For each patient group, the median values per time point are connected with a line. In each panel, the upper and lower horizontal lines indicate the 95th and 5th percentiles of 29 healthy CMV-seropositive HLA-A2\(^+\) individuals, respectively. SCT, stem cell transplantation.
Among CMV-seropositive patients, all 8 recipients of grafts without detectable A2-NLV–specific CD8+ T cells needed preemptive GCV treatment versus 3 of 8 recipients of grafts with detectable A2-NLV–specific CD8+ T cells (P = .03). Furthermore, the number of A2-NLV–specific CD8+ T cells transferred with the graft was inversely correlated with the number of preemptive GCV treatment courses administered (r = −0.61; P = .01; Figure 5). Among CMV-seropositive SCT recipients, CMV disease occurred in 4 of 8 patients (50%) receiving a graft without detectable A2-NLV–specific CD8+ T cells (ie, < 0.1 × 10^3 cells/kg), and none of the 8 patients receiving a graft with detectable A2-NLV–specific CD8+ T cells developed CMV disease (P = .08).

Our key findings are the following: (1) failure to recover A2-NLV–specific CD8+ T cells after SCT by CMV-seropositive recipients developing CMV viremia was associated with the development of CMV disease; (2) the number of A2-NLV–specific CD8+ T cells in the grafts administered to CMV-seropositive SCT recipients is inversely correlated with the number of recurrent CMV infections after SCT, requiring preemptive GCV treatment; and (3) among CMV-seropositive recipients, recurrent CMV antigenemia and CMV disease occurred significantly more frequently after SCT from a CMV-seronegative than from a CMV-seropositive donor.

Our results indicate that protection against progressive CMV infection and CMV disease is being conferred by (1) CMV-specific memory T lymphocytes transferred with the grafts and (2) the development of a CMV-specific cellular immune response after SCT. In line with our findings, Cwynarski et al15 found that reconstitution of CMV-specific CD8+ T cells to levels more than 10 × 10^3 μL protected against CMV disease. These combined results confirm earlier studies based on functional assays, ie, cytotoxicity assays to monitor CMV-specific CD8+ T cells3,16 and lymphoproliferation assays to monitor CMV-specific CD4+ T cells.3,16

With respect to early recovery of the CMV-specific immune response, Cwynarski et al found, in CMV-seropositive patients, that CMV-specific CD8+ T-cells became detectable in all of 12 recipients of SCT from a CMV-seropositive donor (between 21 and 116 days after SCT), whereas CMV-specific CD8+ T cells regenerated only in 1 of 5 recipients of SCT from a CMV-seronegative donor (at 149 days after SCT). These data are consistent with earlier findings, ie, that CMV-seropositive recipients of SCT from CMV-seropositive donors regenerate their CMV-specific helper T-cell3,17 and cytotoxic T-cell responses3 more quickly than recipients of SCT from CMV-seronegative donors. In our study, monitoring was started only at 2 months after SCT, and, from that time point onward, no significant effect of donor CMV serology on the rate of CMV-specific CD8+ T-cell reconstitution was apparent. Remarkably, in some of our SCT recipients with CMV antigenemia (even including one recipient of a SCT from a CMV-seronegative donor [patient 1]), as well as in some of Cwynarski’s patients,15 CMV-specific CD8+ T cells had already regenerated to levels well above the normal range at 2 months after SCT. These results are consistent with the hypotheses that, apart from memory T cells in such T cells could not be detected in the remaining 3 grafts. Of note, 2 grafts containing 0.8 and 4.6 × 10^3 A2-NLV–specific CD8+ T cells/kg, respectively, were administered to CMV-seronegative recipients, who did not recover these T cells during 12 months of follow-up.

Among CMV-seropositive patients, all 8 recipients of grafts without detectable A2-NLV–specific CD8+ T cells needed preemptive GCV treatment versus 3 of 8 recipients of grafts with detectable A2-NLV–specific CD8+ T cells (P = .03). Furthermore, the number of A2-NLV–specific CD8+ T cells transferred with the graft was inversely correlated with the number of preemptive GCV treatment courses administered (r = −0.61; P = .01; Figure 5). Among CMV-seropositive SCT recipients, CMV disease occurred in 4 of 8 patients (50%) receiving a graft without detectable A2-NLV–specific CD8+ T cells (ie, < 0.1 × 10^3 cells/kg), and none of the 8 patients receiving a graft with detectable A2-NLV–specific CD8+ T cells developed CMV disease (P = .08).

**Discussion**

The use of HLA-A*0201 tetramers loaded with the CMV pp65-derived NLV peptide enabled us to monitor CMV-specific T-cell immunity by quantitating A2-NLV–specific CD8+ T lymphocytes in HLA-A2+ recipients of an allogeneic, partially T-cell–depleted SCT. Specifically, we studied whether or not quantification of CMV-specific CD8+ T cells in stem cell grafts and monitoring of their rate of recovery after SCT would predict the occurrence of progressive CMV infection and, in particular, CMV disease. Although the number of patients in our study was small (ie, 27, of which 18 were CMV seropositive), several of our conclusions are supported by the recent report of Cwynarski et al15 who studied CMV-specific T-cell reconstitution using tetramer technology in 13 recipients of non–T-depleted sibling SCT and in 11 recipients of unrelated SCT who had undergone in vivo T-cell depletion using the Campath 1H monoclonal antibody.

**Figure 4.** Repopulation of A2-NLV–specific CD8+ T cells after allogeneic, T-cell-depleted SCT. In each panel, the horizontal line indicates the 95th percentile in HLA-A2+ T-cell–depleted SCT.

**Figure 5.** The number of A2-NLV–specific CD8+ T cells transplanted and the number of preemptive ganciclovir courses administered to the respective SCT recipients is inversely correlated. The number of A2-NLV–specific CD8+ T cells transplanted was expressed as the number of transplanted T cells × 10^3 per kg body weight of the recipient; a logarithmic scale was used for the x axis to compress the figure. Spearman rank correlation coefficient is −0.61 (P = .01). GCV, ganciclovir.
the graft, naive T cells may mount a primary immune response against CMV, and/or residual recipient-derived memory T cells may contribute to the regeneration of CMV-specific T cells after SCT.

With respect to long-term recovery of the CMV-specific immune response, we observed that A2-NLV–specific CD8+ T cells reconstituted to lower levels in CMV seropositive patients without (or with very late) CMV antigenemia as compared with those developing CMV antigenemia early after SCT (but without CMV disease). In addition, we did not observe regeneration of A2-NLV–specific CD8+ T cells in CMV-seronegative recipients of grafts from CMV-seropositive donors. Again, these findings are consistent with those of Cwynarski et al15 and suggest that CMV antigenemia (ie, active CMV infection) is needed to stimulate the expansion of A2-NLV–specific CD8+ T cells. In line with these observations, Li et al13 observed in their randomized study of GCV versus placebo as prophylaxis for active CMV infection that GCV prophylaxis until day 100 after SCT was associated with delayed recovery of CMV-specific T-helper and CTL responses and suggested a reduced stimulation of CMV-specific memory T cells because of suppression of CMV replication by GCV. Although this mechanism may also have been operational in our patients, we also propose that a delayed recovery of CMV-specific T-cell immunity per se, especially after SCT from a CMV-seronegative donor, may have caused increased CMV replication and antigenemia, necessitating preemptive GCV therapy.

The structural CMV protein pp65 has been identified as a major source of immunodominant CTL epitopes,4,5 among which the NLV peptide constitutes the major epitope presented by HLA-A2.5,19 The fact that quantification of CD8+ T cells specific for this single peptide only, yielded already highly informative data in this group of HLA-A2+ patients emphasizes the immunodominance of the NLV peptide in the HLA-A2–restricted immune response against CMV. However, the NLV peptide does not stimulate CD8+ T cells in patients with CMV disease and/or residual recipient-derived memory T cells may contribute to the regeneration of CMV-specific T cells after SCT. We are grateful to Mrs N. de Leeuw, Mrs J. Doekharan-van der Sluis, and Mr R. Kester for their technical assistance.

Acknowledgments

References

1. Quinnan GV Jr, Kimani N, Rook AH, et al. Cyto-
   toxic T cells in cytomegalovirus infection: recov-
   ery from cytomegalovirus infection in bone mar-
2. Reusser P, Riddell SR, Meyers JD, Greenberg
   PD. Cytotoxic T lymphocyte response to cyto-
   megalovirus after human allogeneic bone marrow
   transplantation: pattern of recovery and correla-
   tion with cytomegalovirus infection and disease.
3. Li CR, Greenberg PD, Gilbert MJ, Goodrich JM,
   Riddell SR. Recovery of HLA-restricted cytomeg-
   alovirus (CMV)-specific T-cell responses after al-
   logeneic bone marrow transplant: correlation with
   CMV disease and effect of ganciclovir pro-
   Identification of the major late human cytomeg-
   alovirus matrix protein pp65 as a target antigen for
   CD8+ virus-specific cytotoxic T lymphocytes.
   human cytotoxic T-lymphocyte (CTL) response to
   cytomegalovirus is dominated by structural pro-
   tein pp65: frequency, specificity and T-cell recep-
   tor usage of pp65-specific CTL. J Virol. 1996;70:
   7569-7579.
   human CMV-specific memory T cells among the
   CD8+ subset including CD57+, CD27+ and CD45
7. Altman J, Moss PAH, Goulder P, et al. Direct visu-
   alization and phenotypic analysis of virus-specific
   T lymphocytes in HIV-infected individuals. Scien-
8. Engstrand M, Tournay C, Peyrat MA, et al. Char-
   acterization of CMV pp65-specific CD8+ T lym-
   phocytes using MHC tetramers in kidney trans-
   planted and healthy participants. Transplantation.
   detection and immunomagnetic sorting of specific
   T cells using multimers of MHC class I and pep-
   tide with reduced CD8 binding. Nat Med. 2000;6:
   707-710.
10. Broers AEC, Van der Holt B, Van Essew JWJ, et
    al. Increased transplant related morbidity and morta-
    lity in CMV seropositive patients despite
    highly effective prevention of CMV disease after
    allogeneic T-cell depleted stem cell transplanta-
11. Middeldorp JM, Jongsm A, Ter Haar A, Schirm J,
    The TH. Conditions for the detection of IgM and
    IgG antibodies against cytomegalovirus early and
    late antigens by ELISA. J Clin Microbiol. 1984;20:
    763-771.
12. Van der Bij W, Schirm J, Toensra M, Van Son
    WJ, Tegzess AM, The TH. Comparison between
    viremia and antigenemia for detection of cyto-
    megalovirus in blood. J Clin Microbiol. 1989;26:
    2531-2535.
   ment of interstitial pneumonitis due to cytomeg-
   alovirus with ganciclovir and intravenous immune
   globulin: experience of the European Bone Mar-
   row Transplant Group. Clin Infect Dis. 1992;14:
   831-835.

From www.bloodjournal.org by guest on August 31, 2017. For personal use only.


Tetramer-based quantification of cytomegalovirus (CMV)–specific CD8+ T lymphocytes in T-cell–depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection

Jan W. Gratama, Joost W. J. van Esser, Cor H. J. Lamers, Claire Tournay, Bob Löwenberg, Reinder L. H. Bolhuis and Jan J. Cornelissen